TESS Research Foundation originally anticipated clinical trials for a gene therapy targeting SLC13A5 Epilepsy (SLC13A5 Deficiency) to launch by the end of 2022. It’s 2024, so, why haven’t these trials started yet? We know our community...
TESS Research Foundation hosted our 8th SLC13A5 research conference and what a powerful, motivating, and packed two days! We hosted 110 attendees both in person and virtually in Providence, Rhode Island on August 2-3, 2024....
CIRM's support is crucial for advancing our clinical trials. Rare diseases like SLC13A5 Epilepsy are life-long, life-limiting and often life-ending, so the risk benefit profile weighs in favor of trialing genetic therapies to improve outcomes...
A little rain couldn’t keep the TESS community from coming together, dressed to the nines with fascinators and bow ties on Saturday, May 4, to raise more than $200,000 for scientific research and family support...
A Story of Stella and SLC13A5 by Angela Nie. Read the newest book for families affected by SLC13A5. ...
November is Epilepsy awareness month. Epilepsy is one of the most common neurological disorders, affecting people of all ages, but a rare type of genetic epilepsy affects one local family. "Two of my grandchildren have...
TESS Research Foundation has been approved for a $250,000 funding award through the Eugene Washington PCORI Engagement Award Program, an initiative of the Patient-Centered Outcomes Research Institute (PCORI). The funds will support developing a patient-centered...
Just a few years ago, Moderna faced a chorus of doubts over whether its experimental mRNA technology would ever work well enough to become a medicine. After the $36 billion success of its Covid-19 vaccines,...
